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In December 1997, 170 hemorrhagic fever-associated deaths were reported in Garissa District, Kenya.
Laboratory testing identified evidence of acute Rift Valley fever virus (RVFV). Of the 171 persons enrolled
in a cross-sectional study, 31(18%) were anti-RVFV immunoglobulin (Ig) M positive. An age-adjusted IgM
antibody prevalence of 14% was estimated for the district. We estimate approximately 27,500 infections
occurred in Garissa District, making this the largest recorded outbreak of RVFV in East Africa. In multivari-
able analysis, contact with sheep body fluids and sheltering livestock in one’s home were significantly
associated with infection. Direct contact with animals, particularly contact with sheep body fluids, was the
most important modifiable risk factor for RVFV infection. Public education during epizootics may reduce
human illness and deaths associated with future outbreaks.
ift Valley fever virus (RVFV) is a zoonosis that can cause
epizootics and associated human epidemics in Africa (1).
RVFV is a member of the family Bunyaviridae, genus Phlebo-
virus. Epizootics of RVFV occur periodically after heavy rains
that flood natural depressions in the grasslands of sub-Saharan
Africa (2). Flooding allows for the hatching of the primary
vector and reservoir, multiple species of mosquitoes known as
floodwater Aedes, which feed on nearby mammals (3,4). High
levels of viremia in these animals lead to infection of second-
ary arthropod vector species and to subsequent infection of
other mammals and livestock, in which it causes abortions and
death in susceptible animals (5-7). 
Human infection with RVFV was first reported soon after
Daubney and colleagues isolated the virus in 1930 (8). Exten-
sive human disease outbreaks were not reported until 1951,
however, when an estimated 20,000 persons were infected dur-
ing an epizootic of cattle and sheep in South Africa (9). Out-
breaks were reported exclusively from sub-Saharan Africa
until 1977-78, when 18,000 persons were infected and 598
deaths were reported in Egypt (10). Transmission of the virus
to humans is thought to occur by arthropod vectors, aerosols of
blood or amniotic fluid, or other direct contact with infected
animals. RVFV in humans manifests a broad spectrum of dis-
ease, from asymptomatic infection to a benign febrile illness,
to a severe illness in approximately 1%-3% of cases that can
include retinitis, encephalitis, and hemorrhagic fever (11,12).
In addition to the human illness, disability, and suffering,
RVFV outbreaks can result in devastating economic losses
when livestock in an agricultural society are affected (13,14).
The normalized difference vegetation index has a linear
relationship to rainfall in semiarid regions such as East Africa.
Figure 1 depicts the vegetation development (as sensed by
orbiting satellites) in late 1997, indicating elevated rainfall and
the potential for RVFV outbreaks (15). In December 1997, the
Kenyan Ministry of Health (MOH) and the World Health
Organization (WHO) in Nairobi received reports of unex-
plained deaths in the North Eastern Province of Kenya and
southern Somalia. Clinical features included an acute onset of
fever and headache often associated with hemorrhage (hema-
tochezia, hematemesis, and bleeding from other mucosal
sites). Farmers and local veterinary health officials also
reported high rates of spontaneous abortion and death among
domestic livestock. Active surveillance conducted by the
WHO, the Kenya MOH, and international relief organizations
during December 22 to 28 in 18 villages in Garissa District
(population 231,022), North Eastern Province, Kenya, identi-
fied 170 human deaths, reportedly from a hemorrhagic fever.
No clinical specimens were available from the persons who
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had died. However, of 36 blood samples obtained from other
ill persons in these villages that were tested at the National
Institute for Virology and at the Centers for Disease Control
and Prevention (CDC), 17 (47%) had evidence of acute infec-
tion with RVFV by detection of IgM antibodies, virus isola-
tion, or reverse-transcriptase-polymerase chain reaction (RT-
PCR) for viral nucleic acid.
After RVFV was identified as the primary cause of this
outbreak, an international task force led by the Kenya MOH
established surveillance for hemorrhagic fever and other
severe manifestations of infection. Because the surveillance
system identified only those with severe symptoms, the task
force also conducted a cross-sectional study in the human pop-
ulation of the Garissa District to determine the incidence of
recent infection with RVFV and to evaluate risk factors for
infection.
Methods
Site and Population
The investigation was conducted in the Garissa District of
the North Eastern Province of Kenya, which borders southern
Somalia. In 1998, an estimated 231,022 residents living in
Garissa District were distributed among 12 divisions and 84
sublocations (Office of the President, Garissa District Devel-
opment Plan: 1997-2001, unpub. data). In addition to the Ken-
yan residents, 120,000 Somali refugees lived in the district in
1998. Garissa has an arid climate with a predominantly flat
and grassy landscape. Precipitation in the district averages 250
mm to 500 mm annually, varies considerably from year to
year, and occurs in a bimodal pattern with two peaks, in March
through May and October through December. Although a
number of settled towns are dispersed throughout the region, the
rural population is principally composed of nomadic herdsmen. 
Two events hampered surveillance. By January 1998,
floodwater had damaged or covered most of the already poor
roadways in the Garissa District, making them impassable.
Investigators required air transportation to perform surveil-
lance. Additionally, a nationwide nurses’ strike in December
and January greatly decreased the medical personnel in hospi-
tals and clinics, which contributed to the difficulties in provid-
ing patient care and collecting data.
Hemorrhagic Fever Surveillance
Case Definition
A probable case was defined as someone presenting with
fever and bleeding from their gums, nose, eyes, rectum, lungs,
or gastrointestinal tract, between October 1997 (the onset of
flooding) and February 8, 1998. If specimens were available,
diagnostic laboratory tests for RVFV were performed.
Case Ascertainment
In Garissa, active case-finding for hemorrhagic fever was
performed by members of local law enforcement, village
chiefs, and other government officials. Periodic reports were
provided to the district health officers and the task force. We
disseminated a case-report form to all district medical officers
and international relief agencies involved in medical care in
the area. When possible, reports of possible cases were investi-
gated to obtain demographic and clinical information, as well
as blood, stool, or tissue specimens. The WHO Hemorrhagic
Fever Task Force was conducting similar surveillance through-
out Kenya and in southern Somalia and northern Tanzania.
Laboratory
Initially, specimens were transported to the Africa Medical
Research Foundation in Nairobi, where serum specimens were
centrifuged, divided into aliquots, and forwarded to the Viral
Research Center/Kenyan Medical Research Institute. Subse-
quently, a laboratory operated by Médècins du Monde was
established in Garissa to process clinical samples. Within 12
hours of collection, serum specimens were stored at 4°C until
packed and shipped to National Institute for Virology and
CDC for RVFV-specific IgG and IgM antibody enzyme-linked
immunosorbent assay (ELISA), virus isolation, RT-PCR, and
sequencing of the DNA product, or immunohistochemistry
using previously described methods (16-19).
Figure 1. Images from advanced, very high
resolution radiometer instrument on a
National Oceanic and Atmospheric Adminis-
tration satellite comparing normalized differ-
ence vegetation index data (as a surrogate
for rainfall), from December 1996 (A) and
December 1997 (B). Increasing vegetation
is depicted from tan to yellow [predominat-
ing in part (a)], to light and dark green [pre-
dominating in (b)].RESEARCH
140 Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002
Cross-Sectional Survey
Case Definition
For the cross-sectional survey, a laboratory-confirmed case
definition was used. A case of recent infection was defined as
presence of RVFV-specific IgM antibodies by ELISA. Persons
with RVFV-specific IgG antibodies by ELISA and no IgM
antibody were considered to have been infected before this
outbreak. In our initial calculations, we considered persons
with only anti-RVFV IgG antibodies to be protected against
infection. The background prevalence of past RVFV infection
in Kenya is not known, but IgG positivity as high as 40% has
been shown in populations at high risk after epizootics (20). In
contrast, a 1983 study for serologic prevalence of hemorrhagic
fever viruses in Kenya   demonstrated that <1% of persons
sampled had anti-RVFV IgG, but a less sensitive immunofluo-
rescent antibody test was used (21). This study did not include
the North Eastern Province. Additionally, the duration of IgM
antibodies is not well documented. Therefore, a second analysis
included persons with either anti-RVFV IgG or IgM antibodies.
 Sampling
We selected participants for the cross-sectional survey
from the non-refugee population of Garissa District using a
modified multistage cluster design (22). In Kenya, each prov-
ince is divided into divisions that are made up of locations and
then sublocations. We used sublocations as the units for choos-
ing clusters. Thirty clusters (sublocations) were selected from
12 divisions. The number of clusters per division was
weighted to represent population density. Clusters were then
chosen randomly. Seven households were chosen in each clus-
ter by systematic random sampling for a total sample size of
210 persons. The investigating team identified one person in
each household for recruitment into the study. To reflect the
age distribution of the RVFV infection and hemorrhagic fever
cases already identified in the outbreak, we included one child
between 2 and 9 years old, five persons between 10 and 49
years old, and one person  >50 years in each cluster. Between
February 8 and 14, 1998, three field teams interviewed and
obtained samples from 202 persons from 29 clusters. Three of
the selected cluster sites had been destroyed by the flood and
could not be located. Replacement sublocations were sampled
for two of the three destroyed clusters. In one cluster, only six
persons were sampled. In four clusters, children <10 years of
age were not sampled and were replaced by adults.
Data Collection
After informed consent was obtained, a blood specimen
was collected and each participant was interviewed. We used a
standardized questionnaire that included demographic charac-
teristics (age, gender, family size), exposure information (e.g.,
slaughtering practices, butchering, consuming raw meat and
milk), environmental factors (displacement by flood, type of
settlement, loss of livestock), and history of illness between
the start of the floods and the date of the interview. Exposure
to mosquitoes was evaluated through questions about attempts
to reduce bites (i.e., mosquito nets, fires, other methods). Oth-
erwise, all persons were assumed to share a similar risk for
insect bites. Local health workers fluent in English, Kiswahili,
and Somali were trained to administer the questionnaire and
were supervised by an epidemiologist. Interviewers recorded
information in English. 
Laboratory
Blood specimens were kept at ambient temperature for <6
hours. Specimens were processed at the Médècins du Monde
laboratory as noted above. RVFV-specific IgG ELISA, as well
as IgM ELISA, was performed on all blood specimens. At the
time of the cross-sectional survey, there were no reports of
severe manifestations of illness and we believed that virus
transmission was not ongoing. Therefore, virus isolation and
PCR were not performed on these specimens. 
Data Management and Analysis
Data from completed questionnaires were double-entered
into databases by using Epi Info version 6.0 (CDC, Atlanta,
GA). Univariate and multivariable analyses were performed
by using SAS (version 6.12, Cary, NC). Poisson regression
was used with a generalized estimating equations algorithm
and controlled for the clustered nature of the data (23).
Results
Hemorrhagic Fever Surveillance
The hemorrhagic fever surveillance system identified 77
persons with severe febrile illness in Garissa District whose
onset of fever was between November 10, 1997, and February
8, 1998. Fifty-three persons (57% male; median age 28 years,
from 3 to 85 years) met the case definition for hemorrhagic
fever (Figure 2). Of these 53 patients, 10 (19%) had evidence
of acute RVFV infection (Table 1), and another 10 were posi-
tive by the anti-RVFV IgG ELISA. Because few cases were
available for follow-up, case-fatality proportions were not cal-
culated. Of the 24 persons whose illness did not meet the case
definition for hemorrhagic fever, six (25%) had evidence of
acute RVFV infection; one of these six had encephalitis and
another had retinitis. The limited surveillance system also con-
firmed human disease in Tanzania and in Somalia (Figure 3).
Cross-Sectional Survey 
Antibody Prevalence
Of the 202 persons enrolled in the cross-sectional study, 31
(15%) were positive only for anti-RVFV IgG (i.e., previously
infected). Although persons having only IgG antibody were
widely dispersed geographically, the highest prevalence was
found in the Hulugho Division (32%) and the Masalani Divi-
sion (29%). The highest percentage of previous infection by
age group was for persons  >65 years of age (Table 2). Charac-
teristics of the sampled population are provided in Table 2. Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 141
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Of the 171 susceptible persons in the sample, 31 (18%)
were positive for anti-RVFV IgM. The percentage of those
with detectable IgM antibody varied with age; this antibody
was detected in 5% of children <15 years of age, 23% of per-
sons 15 to 65 years of age, and 13% of persons >65 (Table 2).
The age-adjusted prevalence of IgM antibody positivity stan-
dardized to the population of Garissa District was 14% (95%
CI 11-16). Sixteen clusters, representing all 12 of the adminis-
trative divisions in Garissa District, had persons with anti-
RVFV IgM antibody,  indicating recent viral transmission. Of
the 31 persons with serologic evidence of recent infection, 30
(97%) reported having a recent illness, compared with 116
(83%) of the antibody-negative persons (p=0.06); no symp-
toms distinguished recent RVFV-associated illness from other
illness. 
Assuming an age-adjusted IgM antibody prevalence of
14% in the susceptible population, we estimate that approxi-
mately 27,500 persons were infected with RVFV during this
outbreak in Garissa District alone. If the presence of IgG anti-
body were included in the case definition for recent infection,
then the standardized prevalence would increase to 23% (95%
CI 20-26) and would represent approximately 53,000 infected
residents.
Risk Factor Assessment
Certain demographic characteristics (Table 2) were associ-
ated with higher rates of infection as determined by IgM
ELISA, including rural habitation (p=0.02) and household size
of less than four persons (p=0.001). Age <15 years was associ-
ated with a lower rate of recent infection (p=0.05). A large
number of animal contact activities, including herding, milk-
ing, slaughtering, and sheltering animals in the home, were
statistically associated with recent RVFV infection (Table 3).
The association was greatest with sheep-related activities,
especially for those resulting in contact with sheep blood or
body fluids.
Many of the animal contact variables were highly associ-
ated with infection in univariate analysis, but were also highly
correlated. Multivariable analysis of composite variables for
species-specific activities that resulted in similar exposures
and potential confounders demonstrated a significant associa-
tion between recent RVFV infection and persons who had con-
tact with sheep blood, amniotic fluid, or milk (not including
milk consumption; RR 3.0, 95% CI 1.3-6.7) (Table 4). Shelter-
ing any domestic livestock (mostly sheep and goats) in one’s
home during the flood also remained independently and signif-
icantly associated with infection in the multivariable analysis
Figure 2. Temporal distribution of hemorrhagic fever cases, by date of
onset, Garissa District, Kenya, December 1, 1997, to February 14,
1998. Source: CDC, Morbidity and Mortality Weekly Report
1998;47:261-4.
Table 1. Results of testing for laboratory-confirmed cases of 
Rift Valley fever, Garissa District, Kenya, 1997–98
Onset date
Collection 
date
Virus 
isolation RT-PCR
IgM 
ELISA
IgG 
ELISA
12/9/97 12/23/97 + + - -
12/18/97 12/25/97 + + + -
12/18/97 12/26/97 - Not done + +
12/19/97 12/26/97 + + + +
12/21/97 12/26/97 + + + -
12/22/97 01/22/98 Not done Not done + +
12/30/97 01/23/98 Not done + + +
1/18/98 01/22/98 Not done - + +
1/28/98 02/02/98 Not done Not done + +
2/7/98 02/09/98 Not done Not done + -
RT-PCR=reverse transcription-polymerase chain reaction; IG=immunoglo-
bulin; ELISA=enzyme-linked immunosorbent assay.
Figure 3. Geographic distribution of Rift Valley fever outbreak, East
Africa, 1997–98. (Number of confirmed cases / number of cases with
severe febrile illness reported to surveillance system).
Source: CDC, Morbidity and Mortality Weekly Report 1998;47:261-4.RESEARCH
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(RR 3.5, 95% CI 1.3-9.1). Although not significant in univari-
ate analysis, being male also was significantly associated with
infection (RR 1.6, 95% CI 1.0-2.8). Age <15 years was associ-
ated with a reduced risk for infection when controlling for the
other risk factors (RR 0.3, 95% CI 0.06-1.0). Drinking raw
sheep milk was independently associated with infection, but
did not reach statistical significance (RR 1.6, 95% CI 0.9-2.9).
When the analysis was repeated using detection of either
anti-RVFV IgM or IgG as the outcome variable, which effec-
tively doubled the number of cases of RVFV, only contact with
sheep blood or body fluids and sheltering animals in the home
remained significantly associated with illness in the multivari-
able model (data not shown).
Discussion
After heavy rainfall in late 1997, an epidemic of Rift Val-
ley fever among humans accompanied an epizootic among
ungulates in East Africa. From the cross-sectional investiga-
tion in the Garissa District of Kenya, we estimated 27,500
recent human infections with the virus occurred during this
period, making this the largest outbreak of RVFV infection
ever recorded in sub-Saharan Africa. In addition to Garissa
District in the North Eastern Province, we identified recent
human infection associated with hemorrhagic fever or enceph-
alitis in four of Kenya’s six provinces during the 1997-1998
outbreak (CDC, unpub. data). Surveillance also confirmed
human disease in Tanzania, and, for the first time, in Somalia.
Risk factors for human infection identified by this study
included a broad array of activities associated with animal
exposures, but most significantly, contact with sheep (particu-
larly contact with sheep blood or other body fluids), male gen-
der, and housing animals indoors with household members.
Children <15 years of age were significantly less likely to have
had recent RVFV infection.
Persons identified by the surveillance system did not
undergo thorough clinical and laboratory investigations, and
most persons who reported hemorrhaging were not directly
observed by a clinician. Laboratory testing also found evi-
dence of infection with other viral agents (Dengue and Bun-
yamwera  viruses), malaria, shigella dysentery, and
leptospirosis as explanations for some of the persons whose
illness met the hemorrhagic fever case definition, but who
were negative for RVFV infection (CDC, unpub. data). Addi-
tionally, the epidemic appears to have preceded a large out-
break of malaria reported from the same region (24). Other
possible explanations for the persons with fever and hemor-
rhage who had no laboratory evidence of RVFV infection
include an overly sensitive case definition; improper collec-
tion, labeling, handling, and transport of samples; other patho-
gens or toxins; and complications of malnutrition. 
In the cross-sectional study, the case definition for recent
infection was based on the detection of IgM antibody. Unfortu-
nately, the kinetics of the IgM response to RVFV are not well
Table 2. Demographic characteristics of persons enrolled in Rift Val-
ley fever cross-sectional survey, Garissa District, Kenya, 1997–98
Characteristic
Total (%)
n = 202
Priora 
infection 
(% of total) 
 n=31
Susceptibleb
n=171
Acutec 
infection 
(% of 
susceptible)
n=31
Age group (years)
    <15 40 (20) 2 (5) 38 2 (5)
     15 to 65 150 (74) 25 (17) 125  28 (22)
     >65 12 (6) 4 (33) 8  1 (13)
Sex
     Male 103 (51) 16 (16) 87  18 (21)
     Female 99 (49) 15 (15) 84  13 (15)
Rural 
habitation
161 (80) 25 (16) 136  30 (22)
Household  >4 
persons
74 (37)  10 (14) 64  21 (33)
aAnti-RVF IgG antibody-positive (no immunoglobulin M [IgM]).
bTotal screened minus those with prior infection.
cAnti-Rift Valley fever virus IgM antibody-positive.
Table 3. Exposures during previous 90 days, Rift Valley fever (RVF) 
cross-sectional survey, Garissa District, Kenya, 1997–98
Acutea 
infection (%) 
n = 31
No 
infection (%) 
n = 140
Relative 
risk
95% CI
Animal exposures
Sheltered livestock 
in home after flood
27 (87) 63 (45) 5.3 2.3-12.6
Killed an animal 20 (64) 47 (34) 2.4 1.3-4.3
Butchered an 
animal
14 (45) 33 (24) 2.0 1.1-3.6
Skinned an animal 20 (65) 38 (27) 2.4 1.6-3.5
Cooked with meat 20 (65) 48 (34) 2.3 1.1-4.9
Milked animals 25 (80) 59 (42) 3.8 1.9-7.7
Drank raw animal 
milk
30 (97) 89 (64) 8.6 2.0-36.0
Care of animal 
during birth
21 (68) 46 (33) 2.6 1.4-4.9
Disposal of aborted 
fetus
19 (61) 36 (26) 2.8 1.5-5.5
Sheep contactb 25 (81) 48 (29) 6.3 2.9-14.0
Goat contactb 28 (90) 91 (65) 3.1 1.6-6.4
Cow contactb 20 (65) 49 (35) 2.4 1.3-4.5
Camel contactb 5 (16) 17 (12) 1.3 0.5-3.8
Non-animal 
exposures
Home flooded 
since November 
1997
25 (81) 103 (73) 1.3 0.8-2.1
Ill family member 7 (23) 20 (14) 1.6 0.8-3.1
Contact with a 
dead human  body
6 (21) 10 (7) 2.2 1.0-4.6
Use mosquito nets 19 (61) 102 (73) 0.7 0.3-1.4
aAnti-Rift valley fever virus immunoglobulin M antibody-positive.
bContact includes herding, cooking, slaughtering or other body fluid contact 
(except consumption), drinking raw milk.Emerging Infectious Diseases  •  Vol. 8, No. 2, February 2002 143
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described. After natural infection, domestic animals lose a
detectable amount of IgM antibody within 6 months of infec-
tion (25). In a large percentage of humans, experimental inoc-
ulation with a killed vaccine results in an early IgM response
that wanes and is undetectable by 4 to 6 weeks, but this is not a
model for natural infection (26). Of the few clinical infections
that have been followed closely for serologic conversion, IgM
antibody appears around day 5, is absent in 50% by day 45,
and is undetectable 4 months later (12), whereas IgG appears
about day 4 and may persist indefinitely at high titer. 
All blood specimens for our cross-sectional study were
obtained within 12 weeks of the first reported case of hemor-
rhagic fever in Garissa District. Therefore, the IgM antibodies
probably represent recent infection related to the outbreak. If
the IgM antibodies disappear quickly, however, the persons in
whom we detected only IgG antibody may actually have been
infected recently. If we include those persons in the analysis, the
incidence of infection could be as high as 23%, representing an
additional 25,000 infected persons in Garissa District alone. 
Human suffering from RVFV is compounded by the loss of
domestic animals. Livestock owners reported losses of approx-
imately 70% of their animals, with the greatest losses among
sheep and goats. Other infections thought to contribute to ill-
ness among livestock during the flooding included nonspecific
pneumonia, pasteurellosis, contagious caprine pleuropneumo-
nia, contagious pustular dermatitis, bluetongue, foot rot, and
complications of mange (Field Mission of the Food and Agri-
culture Organization of the United Nations, unpub. data).
Because direct contact with blood or body fluids from
viremic animals is an important risk factor for human infection
identified by this study, the high number of domestic animal
abortions and deaths may have increased the risk for humans
developing illness. Many of the early cases were in persons
who had recently been involved in the dissection, slaughter, or
care of sick animals (12,27). A high attack rate has been dem-
onstrated for abattoir workers (28), herdsmen (19), and veteri-
nary personnel (9), all of whom have extensive contact with
animal blood or other body fluids in the course of their work.
In a retrospective investigation in Senegal based on IgG anti-
body positivity, men who assisted with animal births or abor-
tions, and women who treated ill animals were found to be at
increased risk for infection (29). Additionally, the virus has
been isolated from raw milk, and ingestion of raw milk has
been suggested as a risk factor in previous studies (30,31).
Although any animal that develops a high level of viremia
can pose a certain risk for animal-to-human transmission of
virus, we found the greatest association with sheep. In past
RVFV epizootics, sheep have been the most susceptible
domestic animals (1,9,32). After a 2- to 4-day incubation
period, young lambs become listless, and fever and bloody
diarrhea occur; the case-fatality of 90% to 100% is attributed
to hepatic liquefaction (33,34). The disease manifests similarly
in adult sheep, although the case-fatality rate is much lower
(20%-30%). As many as 80% of pregnant ewes abort after
infection (9). The more severe manifestations in sheep are pos-
sibly the result of higher levels of viremia (1010 suckling
mouse intra-cerebral [SMIC] 50% lethal dose/mL), which can
exceed those documented in cows and goats (108-10 SMIC
50% lethal dose/mL) (14). Higher levels of viremia with a
high rate of abortion and deaths result in an increased likeli-
hood of human contact with an infectious inoculum. If the ani-
mal survives acute illness, the virus can be isolated in lower
titers for as long as 3 weeks after illness, making it potentially
dangerous to slaughter an animal, even after the epizootic
appears to be over (33,35).
From this study it is not possible to identify which cases
were infected by mosquitoes and which through direct contact
with animals because we did not gather data on the numbers,
species, prevalence of RVFV infection, or biting rates of mos-
quitos at the time of the outbreak. During February 1998, how-
ever, 3,180 mosquitoes were collected from three trapping
sites in Garissa District. Of the nine captured species, three
have been previously implicated in RVFV transmission to
humans (Anopheles coustani, Mansonia africana, and M. uni-
formis). In our multivariable model, we assumed that the high
mosquito density led to an equal mosquito exposure rate for
the entire population. The association of infection with being
male and >15 years indicates that persons who are more likely
than other groups to perform high-risk behaviors (i.e., adult
men) are more likely to be exposed to the virus. All but one
(97%) of the persons with acute RVFV infection, as identified
by IgM antibody, had recent exposure to either blood, milk, or
abortive materials of a sheep or goat. Most of these people
(87%) also sheltered animals in their home. 
The probability of recurring outbreaks in East Africa and
the potential for spread, by either natural or intentional means,
to non-disease–endemic areas emphasize the necessity of
developing and validating methods to predict, prevent, detect,
and treat Rift Valley fever. Remote sensing satellite technol-
ogy, which can predict rainfall patterns likely to result in dis-
ease emergence, has been suggested as a means to monitor
RVFV activity (15,36). Longitudinal studies using satellite
data to target areas for animal vaccination, enhance surveil-
lance activities for RVFV in animals and humans, and conduct
prospective entomologic studies are in progress. However,
until these methods are validated, simple public health inter-
Table 4. Multivariable risk factor analysis—cross-sectional survey, 
Garissa District, Kenya, 1997–98
Exposure Relative risk  95% CI
Contact with sheep blood or 
body fluids
3.0 1.3-6.7
Sheltering animals in the 
home
3.5 1.3-9.1
Male gender 1.6 1.0-2.8
Age <15 years 0.3 0.06-1.0
Drinking raw sheep milk 1.6 0.9-2.9RESEARCH
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ventions may greatly reduce transmission of the virus. Control
programs aimed at protecting persons during epizootics should
include education about the risks of having contact with
infected animal body fluids. Although this report highlights
the importance of direct animal contact in the transmission of
RVFV to humans, the role of arthropod vectors, particularly in
the virus life cycle in epizootics, cannot be discounted. Control
of mosquito populations during or after heavy rains should be
pursued to prevent animal and human infection. 
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